Aurora Cannabis Inc. reports developments in its global medical cannabis business, including product launches, brand expansion and regulated-market activity across Canada, Europe, Australia and New Zealand. The company serves medical and consumer cannabis markets through brands such as Aurora, MedReleaf, Pedanios, IndiMed, San Raf, Tasty's and Whistler, with GMP-certified manufacturing facilities in Canada and Germany.
Recurring announcements cover new formats such as dried flower, pre-rolls, pastilles and resin cartridges; operating and financial results; international market engagement; capital actions; and governance updates. Aurora's news also reflects its medical-first strategy and use of a global manufacturing network to supply regulated cannabis markets.
Aurora Cannabis (ACB) announced that the Alberta Securities Commission dismissed Curaleaf's application to halt its at-the-market share sale program.
Aurora announced the program in February 2026 to provide financing flexibility for opportunities including increased cultivation capacity and acquisitions. It last used the program on August 18, 2026 and has not used it during Curaleaf's hostile bid process. Aurora's board continues to unanimously recommend that shareholders reject the revised bid by taking no action and not tendering their shares.
Aurora Cannabis (ACB) reaffirmed its board’s unanimous recommendation that shareholders reject Curaleaf’s revised offer for all outstanding common shares.
The offer remains open until December 4, 2026. Aurora’s independent special committee is exploring alternatives, including a possible transaction with third parties or continuing independently. Multiple parties have signed confidentiality and standstill agreements and are examining company information. Discussions are ongoing, and no transaction is assured. The board intends to provide a further recommendation after evaluating alternatives. Shareholders can reject the offer by taking no action; those wishing to withdraw tendered shares can contact their broker or Kingsdale Advisors.
Aurora Cannabis (ACB) completed the expansion of its Leuna, Germany facility, more than doubling its expected annual flower output. The site, renamed Aurora Horizon, received an expanded EU-GMP manufacturing license covering newly built areas. The multi-million-dollar investment increased cultivation capacity. Aurora expects the added capacity to help meet medical cannabis demand in Germany and across European markets.
Aurora Cannabis (ACB) urged shareholders to take no action on Curaleaf's revised takeover bid while its Special Committee begins a review.
The bid covers all outstanding Aurora common shares and offers US$5.00 in implied consideration per share, consisting of 0.4013 Curaleaf subordinate voting shares plus US$1.00 in cash. Shareholders have until at least December 4, 2026, the revised bid expiry date, to consider their options. The Special Committee will review the bid with its advisors before recommending a response to the Board. The Board will then communicate its formal recommendation through a news release and Directors' Circular.
Aurora Cannabis (ACB) maintained its recommendation that shareholders take no action while Curaleaf's proposed revised takeover bid awaits formal filing.
The proposed offer for all outstanding Aurora common shares has revised implied consideration of US$5.00 per share, comprising 0.4013 Curaleaf subordinate voting shares and US$1.00 cash per Aurora share. Curaleaf has not yet filed its Notice of Variation and Change. Aurora's independent Special Committee will review the formal revised offer before the Board issues its recommendation. Shareholders will have until at least December 4, 2026 to consider their options.
Summary not available.
Aurora Cannabis (ACB) reaffirmed its fiscal 2027 Q2 guidance for sequential growth in quarterly net revenue and adjusted EBITDA, supported by recent acquisitions and international strength.
The accretive acquisition of Safari Flower Company, which received EU-GMP certification in July, is expected to add incremental net revenue and adjusted EBITDA and expand critical EU-GMP production capacity. Aurora highlights continued strong, profitable performance in Germany and Poland, including #1 market share by revenue in Poland, and ongoing UK expansion via the acquisitions of Internode Pharma and HAP Pharma Limited. The company reports a strong balance sheet with $149 million in cash as of June 30, 2026 and no debt, and plans continued investment in international markets to drive long-term medical cannabis growth.
Aurora Cannabis (ACB) responded on September 14, 2026 to Curaleaf Holdings' application to halt Aurora's at-the-market (ATM) share program, in the context of Curaleaf's ongoing hostile bid for Aurora.
Aurora states the ATM program was publicly announced in February 2026, over six months before Curaleaf's bid, and is a long-term capital tool to fund international growth, including recent UK acquisitions. Aurora reports that it is debt free with a strong cash position, while citing Curaleaf financial statements that show more than $1 billion of debt, including $500 million of senior secured notes at 11.5% interest as of June 30, 2026. Aurora's board and special committee have unanimously recommended that shareholders reject Curaleaf's hostile offer by taking no action and not tendering, and advise any shareholders who already tendered to withdraw their shares.
Aurora Cannabis (ACB) has appointed biopharmaceutical executive Faris El Refaie as Executive Vice President, Global Commercial, effective September 28, 2026. In this newly created role, he will oversee Aurora's global commercial function, including medical cannabis market strategy, portfolio alignment, customer engagement and commercial capability building across Canada, Europe, Australia, New Zealand and other international markets. El Refaie brings 25 years of experience from leadership roles at JAMP Pharma Group, GSK and AstraZeneca, with a background spanning innovative medicines, oncology, specialty care, vaccines and consumer healthcare.
Curaleaf (CURLF) responded on September 2, 2026 to Aurora Cannabis (ACB), reaffirming its takeover offer as the best value path for Aurora shareholders, highlighting a 45% premium to Aurora’s unaffected share price and a capped price of US$5.00 per share.
The company states the offer equates to a 110% ex‑cash premium and an implied CY2026E adjusted EBITDA multiple of 12.0x, over 68% above Canadian cannabis peers. It argues the US$5.00 cap still represents an 82% premium to Aurora’s 30‑day VWAP on August 10, 2026 and sits in the 92nd percentile of Canadian M&A premiums over 10 years. Curaleaf contrasts its own cash generation – US$50 million operating cash flow and US$17 million free cash flow in H1 2026, and US$145 million over the last twelve months – and access to US$500 million of senior secured notes, with Aurora’s negative operating cash flow, equity dilution of approximately 31% since 2020, and guidance for lower revenue and adjusted EBITDA by fiscal 2027.